{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T07:30:38Z","timestamp":1787729438985,"version":"build-2784847793"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1093\/ehjci\/jeu212","type":"journal-article","created":{"date-parts":[[2014,11,3]],"date-time":"2014-11-03T23:21:58Z","timestamp":1415056918000},"page":"158-165","source":"Crossref","is-referenced-by-count":8,"title":["Food and Drug Administration criteria for the diagnosis of drug-induced valvular heart disease in patients previously exposed to benfluorex: a prospective multicentre study"],"prefix":"10.1093","volume":"16","author":[{"given":"Sylvestre","family":"Mar\u00e9chaux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Rusinaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"Jobic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Ederhy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erwan","family":"Donal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"R\u00e9ant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Arnalsteen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Boulanger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Garban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Vladimir","family":"Ennezat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Jeu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Szymanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Tribouilloy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,11,3]]},"reference":[{"key":"key\n\t\t\t\t20170523175424_JEU212C1","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0140-6736(09)60252-X","article-title":"Drug-induced fibrotic valvular heart disease","volume":"374","author":"Bhattacharyya","year":"2009","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170523175424_JEU212C2","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199708283370901","article-title":"Valvular heart disease associated with fenfluramine-phentermine","volume":"337","author":"Connolly","year":"1997","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170523175424_JEU212C3","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1212\/01.WNL.0000083985.00343.F2","article-title":"Heart valvular disease in patients with Parkinson's disease treated with high-dose pergolide","volume":"61","author":"Van Camp","year":"2003","journal-title":"Neurology"},{"key":"key\n\t\t\t\t20170523175424_JEU212C4","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1365-2265.2012.04349.x","article-title":"No clinically significant valvular regurgitation in long-term cabergoline treatment for prolactinoma","volume":"77","author":"Halperin","year":"2012","journal-title":"Clin Endocrinol"},{"key":"key\n\t\t\t\t20170523175424_JEU212C5","doi-asserted-by":"crossref","first-page":"e10128","DOI":"10.1371\/journal.pone.0010128","article-title":"Benfluorex and unexplained valvular heart disease: a case-control study","volume":"5","author":"Frachon","year":"2010","journal-title":"PLoS ONE"},{"key":"key\n\t\t\t\t20170523175424_JEU212C6","doi-asserted-by":"crossref","first-page":"e38273","DOI":"10.1371\/journal.pone.0038273","article-title":"Echocardiographic evidence for valvular toxicity of benfluorex: a double-blind randomised trial in patients with type 2 diabetes mellitus","volume":"7","author":"Derumeaux","year":"2012","journal-title":"PLoS ONE"},{"key":"key\n\t\t\t\t20170523175424_JEU212C7","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1161\/CIRCULATIONAHA.112.111260","article-title":"Increased risk of left heart valve regurgitation associated with benfluorex use in patients with diabetes mellitus: a multicenter study","volume":"126","author":"Tribouilloy","year":"2012","journal-title":". Circulation"},{"key":"key\n\t\t\t\t20170523175424_JEU212C8","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1161\/01.CIR.102.23.2836","article-title":"Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications","volume":"102","author":"Rothman","year":"2000","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170523175424_JEU212C9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1136\/heartjnl-2012-302239","article-title":"Drug-induced valvular heart disease","volume":"99","author":"Cosyns","year":"2013","journal-title":"Heart"},{"key":"key\n\t\t\t\t20170523175424_JEU212C10","first-page":"1061","article-title":"Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Health and Human Services interim public health recommendations, November 1997","volume":"46","author":"Centers for Disease Control and Prevention","year":"1997","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key\n\t\t\t\t20170523175424_JEU212C11","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJM199809103391103","article-title":"An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo: Sustained-Release Dexfenfluramine Study Group","volume":"339","author":"Weissman","year":"1998","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170523175424_JEU212C12","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1056\/NEJM199809103391101","article-title":"The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs","volume":"339","author":"Khan","year":"1998","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170523175424_JEU212C13","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0002-9149(99)00567-6","article-title":"Echocardiographic prevalence of mitral and\/or aortic regurgitation in patients exposed to either fenfluramine-phentermine combination or to dexfenfluramine","volume":"84","author":"Kancherla","year":"1999","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20170523175424_JEU212C14","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1001\/jama.283.13.1703","article-title":"Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine\/fenfluramine","volume":"283","author":"Gardin","year":"2000","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20170523175424_JEU212C15","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/j.amjcard.2007.06.045","article-title":"Possible association between 3,4-methylenedioxymethamphetamine abuse and valvular heart disease","volume":"100","author":"Droogmans","year":"2007","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20170523175424_JEU212C16","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S0002-9149(98)01064-9","article-title":"Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study)","volume":"83","author":"Singh","year":"1999","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20170523175424_JEU212C17","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0735-1097(00)00744-0","article-title":"Prevalence and correlates of aortic regurgitation in American Indians: the Strong Heart Study","volume":"36","author":"Lebowitz","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20170523175424_JEU212C18","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1093\/ejechocard\/jep023","article-title":"Role of echocardiography in toxic heart valvulopathy","volume":"10","author":"Droogmans","year":"2009","journal-title":"Eur J Echocardiogr"},{"key":"key\n\t\t\t\t20170523175424_JEU212C19","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.1093\/eurheartj\/eht266","article-title":"Frequency of drug-induced valvular heart disease in patients previously exposed to benfluorex: a multicentre prospective study","volume":"34","author":"Tribouilloy","year":"2013","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170523175424_JEU212C20","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.acvd.2011.07.001","article-title":"How can benfluorex-related heart valve disease be identified by echocardiography?","volume":"104","author":"Tribouilloy","year":"2011","journal-title":"Arch Cardiovasc Dis"},{"key":"key\n\t\t\t\t20170523175424_JEU212C21","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.acvd.2013.04.006","article-title":"Impact of selective serotonin reuptake inhibitor therapy on heart valves in patients exposed to benfluorex: a multicentre study","volume":"106","author":"Marechaux","year":"2013","journal-title":"Arch Cardiovasc Dis"},{"key":"key\n\t\t\t\t20170523175424_JEU212C22","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/ejechocard\/jeq031","article-title":"European Association of Echocardiography recommendations for the assessment of valvular regurgitation. Part 2: mitral and tricuspid regurgitation (native valve disease)","volume":"11","author":"Lancellotti","year":"2010","journal-title":"Eur J Echocardiogr"},{"key":"key\n\t\t\t\t20170523175424_JEU212C23","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/ejechocard\/jeq030","article-title":"European Association of Echocardiography recommendations for the assessment of valvular regurgitation. Part 1: aortic and pulmonary regurgitation (native valve disease)","volume":"11","author":"Lancellotti","year":"2010","journal-title":"Eur J Echocardiogr"},{"key":"key\n\t\t\t\t20170523175424_JEU212C24","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1093\/ejechocard\/jeq027","article-title":"Restrictive organic mitral regurgitation associated with benfluorex therapy","volume":"11","author":"Tribouilloy","year":"2010","journal-title":"Eur J Echocardiogr"},{"key":"key\n\t\t\t\t20170523175424_JEU212C25","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/pds.3642","article-title":"Adverse effects of benfluorex on heart valves and pulmonary circulation","volume":"23","author":"Szymanski","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"key\n\t\t\t\t20170523175424_JEU212C26","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0002-9149(00)01362-X","article-title":"Prevalence and correlates of mitral regurgitation in a population-based sample (the Strong Heart Study)","volume":"87","author":"Jones","year":"2001","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20170523175424_JEU212C27","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S0735-1097(96)00563-3","article-title":"Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study","volume":"29","author":"Stewart","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20170523175424_JEU212C28","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1161\/CIRCULATIONAHA.104.486738","article-title":"Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies","volume":"111","author":"Freeman","year":"2005","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170523175424_JEU212C29","first-page":"688","article-title":"Valvular heart disease associated with benfluorex therapy: high prevalence in patients with unexplained restrictive valvular heart disease","volume":"12","author":"Boudes","year":"2011","journal-title":"Eur J Echocardiogr"}],"container-title":["European Heart Journal - Cardiovascular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ehjcimaging\/article-pdf\/16\/2\/158\/17465071\/jeu212.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,24]],"date-time":"2017-08-24T08:39:43Z","timestamp":1503563983000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcimaging\/article-lookup\/doi\/10.1093\/ehjci\/jeu212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,3]]},"references-count":29,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2014,11,3]]},"published-print":{"date-parts":[[2015,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjci\/jeu212","relation":{},"ISSN":["2047-2412","2047-2404"],"issn-type":[{"value":"2047-2412","type":"electronic"},{"value":"2047-2404","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11,3]]}}}